Novo Nordisk's Ryzodeg Approved for Diabetes Treatment in Japan

Danish pharmaceutical company Novo Nordisk (NYSE: NVO  ) announced last week that its diabetes-fighting insulin drug Ryzodeg has been approved for sale in Japan by the Japanese Ministry of Health, Labour, and Welfare.

Ryzodeg is a combination of long-acting insulin agent Tresiba and fast-acting insulin agent NovoRapid -- marketed in the U.S. under the name NovoLog. Nordisk still waits upon FDA approval for Tresiba in the United States. An FDA advisory committee gave a positive opinion of the drug back in November, but it also unanimously voted to advise that Novo Nordisk be required to carry out a study on cardiovascular effects of the drug.

Novo, which some industry observers say could market Tresiba as a potent competitor to Sanofi's (NYSE: SNY  ) blockbuster insulin drug Lantus, has said such a study would cost in excess of $250 million.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2173278, ~/Articles/ArticleHandler.aspx, 10/23/2014 12:17:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement